Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Breast Cancer × Gemcitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 149 Carcinoma, Non-Small-Cell Lung 93 Neoplasms 56 Breast Neoplasms 50 Urinary Bladder Neoplasms 47 Neoplasm Metastasis 42 Lung Neoplasms 41 Ovarian Neoplasms 35 Cholangiocarcinoma 30 Lymphoma 20 Sarcoma 19 Fallopian Tube Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 18 Gallbladder Neoplasms 18 Biliary Tract Neoplasms 18 Recurrence 15 Lymphoma, Non-Hodgkin 15 Hodgkin Disease 13 Carcinoma, Transitional Cell 13 Adenocarcinoma 13 Carcinoma 12 Bile Duct Neoplasms 12 Colorectal Neoplasms 10 Head and Neck Neoplasms 8 Carcinoma, Renal Cell 8 Urethral Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Carcinoma, Ovarian Epithelial 7 Adenocarcinoma of Lung 7 Uterine Cervical Neoplasms 6

Interventions

Fulvestrant 3 Docetaxel 2 Dasatinib 2 vandetanib 1 sonidegib 1 pembrolizumab 1 palbociclib 1 olaparib 1 exemestane 1 cediranib 1 Letrozole 1 Goserelin 1 Gemcitabine 1 Everolimus 1 Capecitabine 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡